Title:
COMPOUND HAVING KINASE INHIBITORY FUNCTION, AND PREPARATION AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/002378
Kind Code:
A1
Abstract:
The present invention provides an HPK1 kinase inhibitor, and the preparation and use thereof. Specifically, the present invention provides a compound represented by formula (I), where the definition of each group is as described in the description. The compound has excellent HPK1 inhibitory activity and therefore can be used to prepare pharmaceutical compositions for treating cancer and other HPK1 activity-related diseases.
Inventors:
JIANG LEI (CN)
CHENG ZHANLING (CN)
ZHAO HAIXIA (CN)
WANG BING (CN)
AO XIANG (CN)
NIE SHICHANG (CN)
QIAO ZHI (CN)
WU DANYI (CN)
LIU SHENGYANG (CN)
ZHANG YI (CN)
ZHANG SHUYUN (CN)
XU YUAN (CN)
SHI QIAN (CN)
FENG ZHIYONG (CN)
XU LINGLING (CN)
SHOU JIANYONG (CN)
JIN XIAN (CN)
ZHANG JIANHUA (CN)
MAO XUDONG (CN)
CHENG ZHANLING (CN)
ZHAO HAIXIA (CN)
WANG BING (CN)
AO XIANG (CN)
NIE SHICHANG (CN)
QIAO ZHI (CN)
WU DANYI (CN)
LIU SHENGYANG (CN)
ZHANG YI (CN)
ZHANG SHUYUN (CN)
XU YUAN (CN)
SHI QIAN (CN)
FENG ZHIYONG (CN)
XU LINGLING (CN)
SHOU JIANYONG (CN)
JIN XIAN (CN)
ZHANG JIANHUA (CN)
MAO XUDONG (CN)
Application Number:
PCT/CN2023/105599
Publication Date:
January 04, 2024
Filing Date:
July 03, 2023
Export Citation:
Assignee:
SHANGHAI ENNOVABIO PHARMACEUTICALS CO LTD (CN)
ENNOVABIO ZHEJIANG PHARMACEUTICALS CO LTD (CN)
ENNOVABIO ZHEJIANG PHARMACEUTICALS CO LTD (CN)
International Classes:
C07D471/04; A61K31/407; A61K31/4162; A61K31/437; A61P35/00; C07D487/04
Domestic Patent References:
| WO2021213317A1 | 2021-10-28 | |||
| WO2018152220A1 | 2018-08-23 |
Foreign References:
| CN114341127A | 2022-04-12 |
Attorney, Agent or Firm:
XU & PARTNERS, LLC. (CN)
Download PDF: